Trials: Dengue Disease

Phase 2 N=1,050 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever · Dengue Hemorrhagic Fever

Primary: STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline…

Sanofi Pasteur, a Sanofi Company Results Feb 2021 4.8% serious AE View details

Phase 2 N=390 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Dengue · Dengue Fever · Dengue Hemorrhagic Fever

Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…

Sanofi Pasteur, a Sanofi Company Results Jun 2019 3.3% serious AE View details

Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Sanofi Pasteur, a Sanofi Company Results Jul 2024 14.4% serious AE View details

Phase 3 N=480 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease

Primary: Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously…

Sanofi Pasteur, a Sanofi Company Results Mar 2020 1.3% serious AE View details

Phase 2 N=90 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue · Dengue Fever · Dengue Hemorrhagic Fever

Primary: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains — NA; NA; NA; NA titers (1/dilution)

Sanofi Pasteur, a Sanofi Company Results Feb 2020 4.4% serious AE View details

Phase 3 N=792 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Dengue · Dengue Hemorrhagic Fever · Yellow Fever

Primary: Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly…

Sanofi Pasteur, a Sanofi Company Results Jul 2019 9.3% serious AE View details

Phase 2 N=51 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Dengue

Primary: Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine. — 3; 1; 11; 1 specified events

U.S. Army Medical Research and Development Command Results Jul 2017 7.8% serious AE View details

Phase 3 N=624 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue · Dengue Hemorrhagic Fever

Primary: Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio…

Sanofi Pasteur, a Sanofi Company Results Jul 2019 6.1% serious AE View details

Phase 2 N=118 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever · Dengue Hemorrhagic Fever

Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD63 Compared to the Third CYD…

Sanofi Pasteur, a Sanofi Company Results Jun 2019 4.2% serious AE View details

Phase 2 N=251 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever · Dengue Hemorrhagic Fever

Primary: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine…

Sanofi Pasteur, a Sanofi Company Results Jun 2019 9.6% serious AE View details

Phase 3 N=528 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease

Primary: Geometric Mean Titers (GMTs) Against Each Gardasil Vaccine Human Papillomavirus (HPV) Antigen (HPV-6, HPV-11, HPV-16, HPV-18) 28 Days After Last Gardasil Vaccination in…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 3.6% serious AE View details

Phase 2 N=300 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever

Primary: Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or…

Sanofi Pasteur, a Sanofi Company Results Jul 2019 2.0% serious AE View details

Phase 3 N=20,869 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue Fever · Dengue Hemorrhagic Fever · Dengue

Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue…

Sanofi Pasteur, a Sanofi Company Results Mar 2019 12.8% serious AE View details

Phase 3 N=10,275 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue · Dengue Fever · Dengue Hemorrhagic Fever

Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD…

Sanofi Pasteur, a Sanofi Company Results Nov 2015 14.6% serious AE View details

Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

Dengue

Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants

University of Maryland, Baltimore Results Apr 2025 5.0% serious AE View details

Clinical Trial Search

Phase 2 N=1,050 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Phase 2 N=390 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Phase 3 N=480 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Phase 2 N=90 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Phase 3 N=792 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Phase 2 N=51 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Phase 3 N=624 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Phase 2 N=118 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Phase 2 N=251 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Phase 3 N=528 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Phase 2 N=300 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Phase 3 N=20,869 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Phase 3 N=10,275 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)